Safety and Effectiveness of the Genous Endothelial Progenitor Cell-Capture Stent: Follow-Up to 5 Years

AIMS: To evaluate the long-term clinical outcomes following percutaneous coronary intervention (PCI) with the Genous stent in an unselected population. METHODS: All patients admitted to a single center who underwent PCI using the GS exclusively, between May 2006 and May 2012, were enrolled, and a clinical follow-up of up to 60 months was carried out. The primary endpoint of major adverse cardiac event (MACE) rate was defined as the composite of cardiac death, acute myocardial infarction (AMI), and target lesion revascularization (TLR). RESULTS: Of the 450 patients included (75.1% male; 65.5 ± 11.7 years), 28.4% were diabetic and acute coronary syndrome was the reason for PCI in 76.4%. Angioplasty was performed in 524 lesions using 597 Genous stents, with angiographic success in 97.1%. At a median of 36 months of follow-up (range, 1-75 months), MACE, AMI, TLR, stent restenosis (SR), and stent thrombosis (ST) rates were 15.6%, 8.4%, 4.4%, 3.8%, and 2.2%, respectively. Between 12 and 24 months, the TLR, SR, and ST rates practically stabilized, up to 60 months. Bifurcation lesions were independently associated with MACE, TLR, and SR. CONCLUSION: This is the first study reporting clinical results with the Genous stent up to 60 months. The Genous stent was safe and effective in the long-term, in an unselected population.

Nova Abordagem ao Diagnóstico da Sindroma de Alport: Pesquisa da Cadeia α5 do Colagénio Tipo IV na Pele

Em 2000, os autores iniciaram no Serviço de Nefrologia do Hospital de Curry Cabral, um protocolo de avaliação do papel do estudo imunopatológico da biópsia cutânea no diagnóstico da Sindroma de Alport (SA). A SA é uma doença hereditária, secundária a um defeito do colagénio tipo IV (col. IV), principal componente das membranas basais. O col. IV é constituído por 6 cadeias distintas (α1 a α6). A cadeia α5 está presente nas membranas basais glomerulares e da epiderme (MBE). Em cerca de 85% dos casos de SA (forma de transmissão ligada ao cromossoma X) verifica-se uma alteração da cadeia α5, com consequente ausência ou intermitência desta cadeia, na MBE. O objectivo deste trabalho foi pesquisar a presença da cadeia α5 do col. IV na MBE, e consequentemente avaliar o papel da biópsia cutânea no diagnóstico da SA. Para o efeito estudámos as biópsias cutâneas de dezanove indivíduos pertencentes a seis famílias distintas. Em cada uma das famílias havia pelo menos um indivíduo com história de SA. As biópsias cutâneas foram avaliadas por método de imunofluorescência indirecta, com antisoros dirigidos às cadeias α1, α3 e α5 do col. IV. No padrão normal há a presença das cadeias α5 e α1 e ausência de α3 na MBE.Verificou-se a ausência de α5 na MBE em quatro homens com SA enquanto que um caso de SA apresentou um padrão positivo. Nas mulheres com SA verificámos a intermitência da α5. Nas sintomáticas, mas sem doença, obtivémos um padrão de intermitência da α5 em três casos e um padrão positivo em três casos. Nas três mulheres assintomáticas, os padrões foram igualmente positivos. Em todos os espécimes biópticos verificou-se a presença de α1 (controlo positivo) e a ausência de α3 (controlo negativo). Realçamos o valor da biópsia cutânea no diagnóstico da SA. Este método é particularmente relevante no homem, onde a ausência da α5 na MBE determina o diagnóstico da SA com forma de transmissão ligada ao cromossoma X. Nas mulheres verificam-se dois padrões possíveis, positivo ou intermitente. A intermitência estará relacionada com a presença de SA ou estado portador. Assim consideramos que a biópsia cutânea deverá ser o primeiro passo na marcha diagnóstica para a SA em qualquer doente em que se suspeite desta patologia.

Novel FGFR1 Mutations in Kallmann Syndrome and Normosmic Idiopathic Hypogonadotropic Hypogonadism: Evidence for the Involvement of an Alternatively Spliced Isoform

OBJECTIVE: To determine the prevalence of fibroblast growth factor receptor 1 (FGFR1) mutations and their predicted functional consequences in patients with idiopathic hypogonadotropic hypogonadism (IHH). DESIGN: Cross-sectional study. SETTING: Multicentric. PATIENT(S): Fifty unrelated patients with IHH (21 with Kallmann syndrome and 29 with normosmic IHH). INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Patients were screened for mutations in FGFR1. The functional consequences of mutations were predicted by in silico structural and conservation analysis. RESULT(S): Heterozygous FGFR1 mutations were identified in six (12%) kindreds. These consisted of frameshift mutations (p.Pro33-Alafs*17 and p.Tyr654*) and missense mutations in the signal peptide (p.Trp4Cys), in the D1 extracellular domain (p.Ser96Cys) and in the cytoplasmic tyrosine kinase domain (p.Met719Val). A missense mutation was identified in the alternatively spliced exon 8A (p.Ala353Thr) that exclusively affects the D3 extracellular domain of FGFR1 isoform IIIb. Structure-based and sequence-based prediction methods and the absence of these variants in 200 normal controls were all consistent with a critical role for the mutations in the activity of the receptor. Oligogenic inheritance (FGFR1/CHD7/PROKR2) was found in one patient. CONCLUSION(S): Two FGFR1 isoforms, IIIb and IIIc, result from alternative splicing of exons 8A and 8B, respectively. Loss-of-function of isoform IIIc is a cause of IHH, whereas isoform IIIb is thought to be redundant. Ours is the first report of normosmic IHH associated with a mutation in the alternatively spliced exon 8A and suggests that this disorder can be caused by defects in either of the two alternatively spliced FGFR1 isoforms.